Inhibiteur UCH-L1

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Cell permeable: no

Reversible: yes

Product competes with ATP.

Primary TargetUCH-L1

General description

A potent, reversible, competitive, and active site-directed inhibitor of ubiquitin C-terminal hydrolase L1 (UCH-L1) (K_i = 400 nM; IC₅₀ = 880 nM). Exhibits ~28-fold greater selectivity for UCH-L1 compared to UCH-L3 (Cat. No. 662090). Shown to increase proliferation of the UCH-L1-expressing tumor cell line, SH-SY5Y, at a concentration of 5 µM. Useful tool for studying the roles of UCH-L1 in cancer, Parkinson′s disease, and other neurological disorders. Cell-permeability is reported to vary from cell type to cell type.

An isatin O-acyl oxime compound that acts as a potent, reversible, competitive, and active site-directed inhibitor of UCH-L1 (K_i = 0.40 µM; IC₅₀ = 0.88 µM) with ~28-fold greater selectivity over UCH-L3 (Cat. No. 662090). Shown to increase proliferation of UCH-L1 expresssing tumor cell line SH-SY5Y at 5 µM. A useful tool for studying the roles of UCH-L1 in cancer, Parkinson's disease, and other neurological disorders. Permeability may vary from cell type to cell type.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Liu, Y., et al. 2003. Chem. Biol.10, 837.

Packaging

Packaged under inert gas

10 mg in Glass bottle

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Carcinogenic / Teratogenic (D)